首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase
【24h】

Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase

机译:indryl羟胺作为吲哚胺的锅或双抑制剂2,3-二氧基酶-1,indoleamine 2,3-二氧化酶-2和色氨酸二恶英酶

获取原文
获取原文并翻译 | 示例
           

摘要

Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer. Significant evidence implicates them in a range of inflammatory and immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control. Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research. This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2. (C) 2018 Elsevier Masson SAS. All rights reserved.
机译:色氨酸(TRP)分解酶在癌症的发展中发挥着重要和复杂的作用。 重要证据将它们视为一系列炎症和免疫抑制活动。 鉴于吲哚胺的抑制剂2,3-二氧基酶-1(IDO1),并在临床中分析,已经针对色氨酸二恶英酶(TDO)和吲哚胺2,3-二恶英酶-2(IDO2)描述了更少的抑制剂。 最近涉及癌症,炎症和免疫控制。 因此,这些TRP分解酶的双重或PAN抑制剂的发展可以代表治疗重要的研究领域。 这是描述IDO1,TDO和IDO2的双重和PAN抑制剂的开发的第一个报告。 (c)2018年Elsevier Masson SAS。 版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号